| Literature DB >> 25942065 |
Alan J Connor, Vasileios T Papastavrou, Roxane J Hillier, Ayad Shafiq.
Abstract
Intravitreal bevacizumab is an increasingly common treatment choice for posterior retinopathy of prematurity. Despite concern about its systemic effects, there have been few studies on the lowest effective dose. The authors describe a case that was successfully treated with 0.16 mg of bevacizumab, the first time this dose has been reported. Copyright 2015, SLACK Incorporated.Entities:
Mesh：
Substances：
Year: 2015 PMID： 25942065 DOI： 10.3928/01913913-20150421-11
Source DB: PubMed Journal: J Pediatr Ophthalmol Strabismus ISSN： 0191-3913 Impact factor: 1.402